New Discovery Reveals Potential Treatment for Childhood Brain Tumors

• Scientists at Lund University and Université de Montréal discovered that both the synthetic molecule UM171 and specific KBTBD4 gene mutations target and break down the CoREST protein structure inside cells.
• While UM171 induces temporary changes in stem cell maintenance, KBTBD4 mutations lead to a sustained deficiency of CoREST, trapping cells in an immature, stem-like state that fuels medulloblastoma pathogenesis.
• High-throughput drug screening identified histone deacetylase (HDAC) inhibitors as effective counteragents to these mutations, pointing toward a viable path for drug repurposing in embryonal brain tumors.

The discovery centers on the molecular mechanics of medulloblastoma, which remains the most prevalent malignant pediatric brain tumor. Affecting roughly 15 to 20 children annually in Sweden, medulloblastoma belongs to a class of embryonal malignancies believed to originate when immature progenitor cells fail to undergo proper terminal differentiation, persisting instead in an active state of division.

Cellular Convergence of UM171 and KBTBD4 Mutations

The insight emerged from parallel investigations into blood stem cells and pediatric oncology. UM171, a synthetic molecule originally developed at Université de Montréal, is utilized in stem cell research to expand blood stem cells outside the body by preventing their maturation and promoting self-renewal. Recent scientific literature from groups including Lund University established that UM171 operates by engaging a cellular protein designated KBTBD4, inducing the degradation of a vital transcriptional corepressor complex known as CoREST.

According to Agatheeswaran Subramaniam, a researcher at Lund University, somatic mutations in the KBTBD4 gene—genetic alterations detected in a subgroup of aggressive pediatric medulloblastomas—trigger this exact same breakdown of the CoREST complex. “Although the causes differ, the result is the same – the structure breaks down,” Subramaniam stated in published findings.

While pharmacological exposure to UM171 exerts a transient, reversible effect on the cell, oncogenic KBTBD4 mutations inflict a long-standing deficit of the CoREST structure. As doctoral student Rohit Sivaprasad noted, this persistent absence traps cells in an undifferentiated, stem-like phenotype, directly facilitating embryonal tumorigenesis.

Therapeutic Interventions and Drug Repurposing Screens

Because these aggressive pediatric brain tumors are exceptionally difficult to model in vitro due to their emergence during early developmental windows, researchers required alternative strategies to evaluate therapeutic vulnerabilities. Through large-scale pharmacological screening, the Lund University team identified that HDAC inhibitors successfully counteract the downstream effects driven by KBTBD4 mutations.

HDAC inhibitors modulate chromatin structure and gene transcription by blocking histone deacetylase enzymes. This regulatory mechanism offers a clinically viable approach via drug repurposing, allowing investigators to leverage already approved pharmacological agents for a devastating pediatric disease area.

The transition from fundamental stem cell biology to clinical trials requires rigorous validation. As Subramaniam outlined in the scientific disclosures, the initial mechanistic insights were mapped using hematopoietic models, establishing a clear rationale for subsequent preclinical evaluations in medulloblastoma tumors.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*